CD44 antibody, chimeric antigen receptor and application thereof

A chimeric antigen receptor, human-mouse chimeric antibody technology, applied in the field of biomedicine, can solve the problems of missing target selection, weak tumor cell killing ability, and unsatisfactory results of glioma, and achieve good affinity and Specific, excellent anti-tumor effect

Active Publication Date: 2022-04-12
BEIJING NEUROSURGICAL INST
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology improves on how well it works with certain types of proteins called CTRs (Carcinoma Transmembrane T Cell Receptors). These proteins are involved in cell adhesion during inflammation processes that can lead cancer cells from spreading throughout their body. By combining this type of molecule into an immunotherapy agent like CRISPR/Cas9, researchers have shown promising results for developing effective treatments against tumours such as lung carcinomas.

Problems solved by technology

This patented technical problem addressed in this patents relates to improving methods for treating brain malignancies like astrocytoma without losing their effectiveness due to poor selectivity between normal and transformed areas during therapy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD44 antibody, chimeric antigen receptor and application thereof
  • CD44 antibody, chimeric antigen receptor and application thereof
  • CD44 antibody, chimeric antigen receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] This example is used to illustrate the preparation of CD44 antibody.

[0077] 1. Culture hybridoma cells

[0078] After recovering the hybridoma cell lines, culture them until the number of cells expands to about 1×10 7 At 1000rpm×5min, the cells were collected by centrifugation.

[0079] 2. Extraction of cellular RNA

[0080] In an ultra-clean workbench environment, add 1ml Trizol reagent to the centrifuged cells, let it stand for 5min, add 2mL of chloroform, shake vigorously for 15sec, let stand at room temperature for 3min, 12000rpm×15min, transfer the upper water sample layer to a new EP tube, add 0.5 mL isopropanol, let stand at room temperature for 10min. 12000rpm×10min. Discard the supernatant, add 1mL 75% ethanol, 7500rpmx5min, dry the precipitate, add 50μL double distilled water. The purity was identified and quantified by agarose electrophoresis, and stored at -70°C for future use.

[0081] 3. Prepare cDNA by reverse transcription

[0082] 1 μL total cellu

Embodiment 2

[0092] This example is used to illustrate the construction of a chimeric antigen receptor expression vector.

[0093] (1) Using the full sequence synthesis method, synthesize the nucleotide sequences shown in Table 1 respectively:

[0094] Table 1

[0095]

[0096] (2) Using pLVX-IRES-ΔNGFR (purchased from Clontech, Cat. No. 631982) as a vector, inserting the two nucleotide sequences (SEQ ID NO: 11 and 15) synthesized in step (1) respectively by conventional methods, Two kinds of lentiviral expression vectors of this example were obtained. At the same time, conventional methods were used to construct a plasmid overexpression vector containing SEQ ID NO:13.

Embodiment 3

[0098] This example is used to illustrate the binding activity of the recombinant anti-CD44 single chain antibody in this case to glioma tumor stem cells.

[0099] (1) The plasmid overexpression vector constructed in Example 2 was used for transfection, amplification and protein purification of Escherichia coli according to the following methods.

[0100] (2)Protein expression and purification process:

[0101] Transform the constructed plasmid into BL21 DE3 competent cells, inoculate the resistant LB plate medium, and grow overnight; select 6 single clones on the transformed plate, and inoculate 3ml of resistant liquid medium respectively; culture at 37°C, 220RPM until OD600nm 0.5- 0.6, add 0.5mM IPTG to induce expression at 20°C for 3.5 hours; collect the bacteria by centrifugation, sonicate, and detect the expression by SDS-PAGE. Analysis of small sample expression results: the protein is expressed in both the supernatant and the inclusion body, and soluble expression and pur

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biomedicine, in particular to a CD44 antibody, a chimeric antigen receptor and application of the chimeric antigen receptor. The CD44 antibody or the antigen binding fragment thereof provided by the invention has relatively good affinity and specificity to CD44, and the chimeric antigen receptor containing the CD44 antibody fragment has an excellent anti-tumor effect.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner BEIJING NEUROSURGICAL INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products